Health Care Activity – Page 16

Life Sciences Senior Associate: Evaluating Opportunities in Therapeutics, Diagnostics, and Health Tech

2 years ago talkbio0Tagged Diagnostics, diligence, Evaluation, Life Sciences Senior Associate, research tools, Technology, Health Care

Life Sciences Senior Associate, Therapeutics, Diagnostics, Research Tools, Health Technology, Opportunity Evaluation, Diligence

EU Regulators Confirm No Link Between GLP-1 Drugs and Suicidal Thoughts

2 years ago talkbio0Tagged European Medicines Agency, Evaluation, Feeling suicidal (finding), Glucagon-Like Peptide 1, Ozempic, Wegovy

GLP-1 drugs, Ozempic, Wegovy, European Medicines Agency (EMA), No link to suicidal thoughts, Investigation

EMA Dispels Link Between GLP-1 Receptor Agonists and Suicidal Ideation Risk New

2 years ago talkbio0Tagged agonists, Continuous, Diabetes, Glucagon-Like Peptide-1 Receptor, Mental association, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, pharmacovigilance activities, Preventive monitoring, Suicidal ideation risk, Weight-Loss Agents

EMA, GLP-1 receptor agonists, Diabetes and weight-loss drugs, Suicidal ideation risk, No causal association, Pharmacovigilance activities, Continued monitoring

FDA Approves Vadadustat (Vafseo) for Anemia in Chronic Kidney Disease Patients on Dialysis and Daprodustat (Jesduvroq) for Dialysis-Dependent CKD Adults

2 years ago talkbio0Tagged Anemia, Approved, Black Box Warning, Chronic Kidney Diseases, Daprodustat, Effectiveness, Hemoglobin concentration result, Jesduvroq, Oral Medication, post-marketing safety, Safety, United States Food and Drug Administration, vadadustat, Vafseo

Anemia, Chronic Kidney Disease (CKD), Vadadustat (Vafseo), Daprodustat (Jesduvroq), Oral medication, FDA approval, Hemoglobin levels, Black Box Warning, Efficacy and safety data, Post-marketing safety data

AstraZeneca Joins Price Cap Movement for Inhalers Following Boehringer Investigation

2 years ago talkbio0Tagged AstraZeneca, Evaluation, Inhaler, Prices, SmithKline Beecham

Evaluation, Inhaler, AstraZeneca, SmithKline Beecham, Prices

Biden Proposes Expansion of Medicare Drug Price Negotiation Program

2 years ago talkbio0Tagged Bidens, drug price, Health Care, Increased, Mediation, Medicare, scrutiny

Biden, Medicare, Drug Prices, Negotiation, Increased Scrutiny, More Drugs, Health Care Policy

NICE Rejects Coverage for AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Enhertu Due to Cost-Effectiveness Concerns

2 years ago talkbio0Tagged AstraZeneca, Cost Effectiveness, Coverage rejection, Daiichi Sankyo, Enhertu, Health Services, National, Malignant neoplasm of breast, Nitroglycerin/Sodium Citrate/Ethanol Solution, Technology

NICE, Enhertu, AstraZeneca, Daiichi Sankyo, Breast cancer, Cost-effectiveness, Coverage rejection, Technology Appraisal, National Health Service (NHS)

“Regulating Hope Amidst Uncertainties: Novel ALS Treatments Face Complex Challenges”

2 years ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Antisense Therapy, Approved, Clinical Trials, masitinib, Patient advocacy, regulatory uncertainty, Relyvrio, risk-benefit analysis, United States Food and Drug Administration

ALS Treatments, Regulatory Uncertainty, Clinical Trials, Relyvrio, Masitinib, Antisense Therapy, Risk-Benefit Analysis, FDA Approval, Patient Advocacy